Home › Targets › BTK
Radioligand therapy target profile

BTK: IHC Expression in Cancer and Radioligand Target Profile

Bruton tyrosine kinase · Ensembl ENSG00000010671 · Data updated 2026-11-01

BTK, Bruton tyrosine kinase, is a cell-surface protein. In Human Protein Atlas immunohistochemistry, BTK staining is highest in lymphoma (100% of samples positive), glioma (83% of samples positive) and skin cancer (17% of samples positive). Clinical status: FDA-approved drug (any modality).

Is BTK the right target for your program? Rank it against 15,000 targets on dosimetry, internalization and clinical risk.

Analyze BTK free
LocalizationCell-Surface
Top cancer (IHC)Lymphoma
InternalizationNot assessed
Clinical stageFDA-approved drug (any modality)
Active trialsSee ClinicalTrials.gov
Cancer association (Open Targets)0.82

Is BTK a good radioligand therapy target?

Scored against the six criteria that decide whether a protein can become a radioligand therapy:

BTK IHC staining by cancer type

Protein expression of BTK across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.

Cancer typeIHC scoreLevel% positive
Lymphoma0.92High100%
Glioma0.31Medium83%
Skin Cancer0.11Low17%
Breast Cancer0.07Low11%
Melanoma0.06Low8%
Testicular Cancer0.06Low8%

Not detected by IHC in: colorectal cancer, head and neck cancer, ovarian cancer, kidney cancer, thyroid cancer, bladder cancer, neuroendocrine tumors, cervical cancer, lung cancer, pancreatic cancer, prostate cancer, gastric cancer, endometrial cancer, liver cancer.

Is BTK internalized?

Nuclens has not yet extracted internalization evidence for BTK. Internalization matters for radioligands because an internalizing receptor traps the radionuclide inside the tumor cell. Run a free analysis to pull the latest literature.

BTK clinical trials

FDA-approved drug (any modality). Nuclens hasn't indexed trials for BTK yet. Search ClinicalTrials.gov for BTK trials.

BTK normal tissue expression

Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See BTK in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.

BTK gene essentiality (DepMap)

CRISPR knockout effect across 1252 cancer cell lines: -0.01 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.

Related lymphoma radioligand targets

c-MET (MET) · CD20 (MS4A1) · HER3 (ERBB3) · CD19 · CD45 (PTPRC) · SSTR2 · CD22 · STEAP2

See all radioligand therapy targets in lymphoma.

See how BTK ranks against 15,000 targets for your indication.

Analyze BTK free

Data sources

Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.

Is BTK the right target for your program? · 5 free analyses, no card Analyze BTK free